Global Polyclonal Antibodies Market, By Product Type (Primary Antibody, Secondary Antibody), Application (Academic Research, Commercial) – Industry Trends and Forecast to 2029.
Global Polyclonal Antibodies Market Analysis and Size
There has been immense growth in the pharmaceutical and biotechnology companies over the past few years. The increased research and development activities and the participation of market players in various growth strategies have largely provided growth to the market. Consequently, such growth determinants are projected to show substantial growth over the forecasted period.
- Global Polyclonal Antibodies Market was valued at USD 997.39 million in 2021 and is expected to reach USD 1554.04 million by 2029, registering a CAGR of 5.70% in 2022-2029. The “primary antibody” accounts for the largest product type segment in the polyclonal antibodies market within the forecasted period due to greater specificity, resulting in increased adoption in research and development activities. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Global Polyclonal Antibodies Market Definition
Polyclonal antibodies are made up of a group of antibodies that represent the body's normal immunological response to an antigen. Repeated immunization of an animal with a chosen antigen is required for polyclonal antibody development. They're a mix of antibodies produced by different B cell lineages. These antibodies are a collection of immunoglobulin molecules that react to a certain antigen and isolate different epitopes on that antigen. Antibodies are often produced by inoculating an appropriate mammal with a virus, such as a rabbit, mouse, or goat. Larger mammals are frequently preferred because they can gather a greater amount of serum. The antigen is injected into the mammal, causing B cells to create immunoglobulin G (IgG) that is specific for that antigen.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Product Type (Primary Antibody, Secondary Antibody), Application (Academic Research, Commercial)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc., (U.S.), Merck KGaA (Germany), Abcam plc (UK), BD (U.S.), Bio-Rad Laboratories Inc., (U.S.), Cell Signaling Technology Inc., (U.S.), F. Hoffmann-La Roche Ltd., (Switzerland), Danaher (U.S.), Agilent Technologies (U.S.), PerkinElmer Inc.,(U.S.), Lonza (Switzerland), GenScript (China), BioLegend, Inc. (U.S.), Illumia Inc., (U.S.), ImmonoPresice Antibodies Ltd (Canada), Fujirebio (Sweden), Analytik Jena GmbH (Germany), Omega BioTek Inc.,(U.S.), Dovetail Genomics (U.S.) and Atlas Antibodies (Sweden)
|
|
Market Opportunities
|
|
Polyclonal Antibodies Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints and challenges. All of this is discussed in detail as below:
Drivers
- Growing Prevalence of Diseases
The global polyclonal antibody market is expected to be driven by an increase in the incidence of infectious diseases and a rise in cancer prevalence, especially across the under developing economies.
Furthermore, the expanding healthcare sector, increase in neurobiology and stem cell research, and the availability of technologically advanced products are also expected to fuel market growth. Moreover, the polyclonal antibodies are highly stable, tolerant of pH and buffer changes which also cushions the market’s growth within the forecasted period. The growing demand for therapeutics antibodies is also projected to bolster the market's growth.
Opportunities
- Growing Research and Development
Moreover, the increase in number of research and development activities across the globe by major pharmaceutical and biotechnology companies are estimated to generate lucrative opportunities for the market.
- Surging Growing Techniques
Additionally, to maintain their positions in the highly competitive market, the companies employ a variety of techniques. Industry leaders in the global polyclonal antibody market use a variety of methods, including partnerships, mergers and acquisitions and collaboration which will further offer numerous growth opportunities for the market.
Restraints/Challenges Global Polyclonal Antibodies Market
- Stringent Regulations
Stringent government regulations and less standard validation process of production are expected to obstruct market growth.
- Low Purity and High Cost
Also, the cost of research antibodies is very high. The factors such as low purity and concentration levels of specific polyclonal antibodies are projected to challenge the polyclonal antibodies market in the forecast period of 2022-2029.
This polyclonal antibodies market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the polyclonal antibodies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Post Covid-19 Impact on Polyclonal Antibodies Market
The polyclonal antibodies market was largely impacted by the outbreak of COVID-19. The coronavirus (COVID-19) epidemic and subsequent lockdowns in several nations throughout the world have had a financial impact on enterprises of all types. The private healthcare sector is one of the areas where the COVID-19 epidemic has had a big impact. The imposition of the lockdown and social distancing restrictions by the government to curb the COVID-19 pandemic outbreak, put a financial strain on the healthcare industry in a number of countries. It led to halt of various operations, impeded the production and supply and other negative effects such as stifling business growth, technology event cancellations, suspensions of new developments and has affected the overall production and sales, limiting the industry's expansion. As a result, the worldwide polyclonal antibody market is projected to be constrained by the COVID-19 pandemic throughout the forecast period.
With a gradual decrease in the disease, the restrictions are likely to relax and the various operations will continue, which will help the market witness a slight increment post COVID-19.
Global Polyclonal Antibodies Market Scope
The polyclonal antibodies market is segmented on the basis of product types and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Primary Antibody
- Secondary Antibody
On the basis of product types, the polyclonal antibodies market is segmented into primary antibody and secondary antibody. The primary antibody segment is registered to hold a dominant share in terms of revenue due to greater specificity which further results in increase adoption in research and development activities.
Application
- Academic Research
- Commercial
On the basis of application, the polyclonal antibodies market is bifurcated into academic research and commercial.
Polyclonal Antibodies Market Regional Analysis/Insights
The polyclonal antibodies market is analyzed and market size insights and trends are provided by country, product types and application as referenced above.
The countries covered in the polyclonal antibodies market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the polyclonal antibodies market because of the continuous ongoing research and development activities along with the high presence of leading players within the region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2029 due to the increasing prevalence of cancer and other diseases along with the growing demand for therapeutics antibodies within the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The polyclonal antibodies market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for polyclonal antibodies market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the polyclonal antibodies market. The data is available for historic period 2010-2020.
Competitive Landscape and Polyclonal Antibodies Market Share Analysis
The polyclonal antibodies market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to polyclonal antibodies market.
Some of the major players operating in the polyclonal antibodies market are
- Thermo Fisher Scientific Inc., (U.S.)
- Merck KGaA (Germany)
- Abcam plc (UK)
- BD (U.S.)
- Bio-Rad Laboratories Inc., (U.S.)
- Cell Signaling Technology Inc., (U.S.)
- F. Hoffmann-La Roche Ltd., (Switzerland)
- Danaher (U.S.)
- Agilent Technologies (U.S.)
- PerkinElmer Inc., (U.S.)
- Lonza (Switzerland)
- GenScript (China)
- BioLegend, Inc. (U.S.)
- Illumia Inc., (U.S.)
- ImmonoPresice Antibodies Ltd (Canada)
- Fujirebio (Sweden)
- Analytik Jena GmbH (Germany)
- Omega BioTek Inc., (U.S.)
- Dovetail Genomics (U.S.)
- Atlas Antibodies (Sweden)
Research Methodology : Global Polyclonal Antibodies Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-polyclonal-antibodies-market
SKU-